November 23, 2009 - LifeVest Presented at AHA Scientific Sessions INVESTOR CONTACT: A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655 MEDIA CONTACT: Diane EganZOLL Medical Corporation+1 (978) email@example.com ZOLL LIFEVEST PRESENTED AT AHA SCIENTIFIC SESSIONS 2009 Patients with End Stage Renal Disease, Transient Risk of SCA and Non-Ischemic Cardiomyopathy Identified November 23, 2009─CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL) announced today that the LifeVest® wearable defibrillator was discussed in three separate scientific presentations at the American Heart Association 2009 Science Session in Orlando, Florida last week. The LifeVest presentations at this premier multidisciplinary international cardiovascular meeting are an important indication of increasing acceptance as a standard of care for patients with a temporary risk of sudden cardiac arrest (SCA). Wojciech Zareba, M.D., Ph.D., Professor of Medicine/Cardiology, University of Rochester Medical Center, authored “Sudden Cardiac Arrest in End-Stage Renal Disease: Successful Resuscitation with Wearable Cardiac Defibrillator (WCD)” that discussed how cardiovascular disease remains the leading cause of mortality in patients with end-stage renal disease (ESRD) and that ventricular tachycardia/ventricular fibrillation (VT/VF) appears to be responsible for the majority of SCA in dialysis patients. Only eight percent of the ESRD population who are eligible for an implantable cardiac defibrillator (ICD) actually receives one because physicians are less likely to refer for ICD implantation due to potential complications (infections, difficulties with venous access) or low life expectancy. Dr. Zareba investigated the hypothesis that the majority of SCA events in dialysis patients would be due to VT/VF and that a WCD would successfully save these patients. Dr. Zareba concluded that VT/VF appears to be responsible for the majority of SCA in dialysis patients and these events can be successfully resuscitated with the WCD. Furthermore, he concluded that the WCD may represent a useful alternative therapy for patients unwilling or unable to receive an ICD or requiring ICD removal. Michael Gold, M.D., Ph.D., Chief of Cardiology, Associate Dean of Interdisciplinary Clinical Programs, Medical University of South Carolina, reviewed data from commercial use of the LifeVest in 2008 during the scientific presentation entitled “Ventricular Arrhythmias for the Clinician.” These data showed that the predominant uses of the LifeVest are for primary prevention indications when a patient’s condition is changing and while permanent SCA risk has not been established or after explantation of an infected ICD. The primary prevention coverage indications for LifeVest include patients with a left ventricle ejection fraction less than or equal to 35% and either prior myocardial infarction, dilated cardiomyopathy, or nonischemic cardiomyopathy. Dr. Gold also discussed data from the WEARIT/BIROAD trial and noted the low unnecessary shock rate of 0.6% per patient month of wear as even better than anticipated. Alan Kadish, M.D., Cardiologist, Northwestern University Feinberg School of Medicine, lecture entitled “Clinical Practice: Case-Based Rx of Arrhythmias”, discussed utilization of the LifeVest for patients of concern in the early treatment of nonischemic cardiomyopathy to avoid unnecessary or premature implantation of an ICD. The LifeVest wearable defibrillator is worn by patients at risk of SCA, providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. “I am pleased at the robust scientific discussion regarding the LifeVest during AHA 2009 Scientific Sessions,” stated Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “The research discussed in these lectures further demonstrates how the LifeVest is continuing to gain acceptance as a standard of care for an expanding number of patients at risk of sudden cardiac arrest.” About ZOLL Medical Corporation ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com. Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, LifeVest are registered trademarks of ZOLL Medical Corporation.